Undecimal Bio Raises €16M to Develop Targeted RNA Medicines
Undecimal Bio raised $18M Seed led by 4BIO Capital and IQ Capital to expand its AI-enabled platform for targeted RNA delivery.
The big picture: Cambridge-based Undecimal Bio, a spin-out from Eleven Therapeutics, announced a €16 million ($18 million) Seed financing round. The funding will expand its DELiveri AI-enabled platform for identifying conjugates that can direct RNA medicines to defined cell types and progress its renovascular programs.
Why it matters:
- Targeted Delivery: RNA interference has transformed the treatment of liver-expressed diseases, but precise delivery to tissues beyond the liver remains a key obstacle limiting the broader therapeutic potential of the modality.
- AI-driven Precision: Undecimal’s DELiveri platform uses AI agents to screen vast chemical spaces, deciphering structure-activity relationships to identify optimal conjugates for cell-specific RNA delivery.
- Unmet Needs: The company is initially focusing on renovascular diseases, an area with significant unmet clinical needs where targeted siRNA could offer durable, pathway-specific silencing of disease-driving pathways.
How it works:
- Combinatorial Chemistry: The DELiveri platform combines massive-scale combinatorial chemistry with transformer-based AI to guide siRNA therapeutics into the tissues that need them.
- Molecular Radars: The technology screens large combinatorial libraries of candidate ligands, converting cells to act as ‘molecular radars’ that detect productive delivery at single molecule resolution.
- Agentic AI: High-throughput data from these screens is analyzed by agentic AI to decode the resulting structure-activity data and identify conjugates capable of carrying siRNA into target cells.
The catch: The RNA therapeutics space is highly competitive, with numerous European biotechs also securing significant funding in 2026 for similar AI-enabled drug discovery and targeted delivery platforms, indicating a crowded market for innovation and talent.
Key Facts
- Company: Undecimal Bio
- Amount: €16M
- Round: Seed
- Investors: 4BIO Capital and IQ Capital (co-lead), Verve Ventures, Harel Tech, Entree Capital, Kerna Ventures, Saras Capital
- Founders: Dr. Yaniv Erlich, Shaul Ilan
- Sector: Targeted siRNA Therapeutics
- Headquarters: Cambridge, UK
AIPressRoom Weekly
Every round we reported this week, the people behind the companies, and the events coming up. One email, every Tuesday.